Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Change in Receivables (2016 - 2022)

Edesa Biotech's Change in Receivables history spans 9 years, with the latest figure at -$126678.0 for Q3 2022.

  • For Q3 2022, Change in Receivables rose 83.73% year-over-year to -$126678.0; the TTM value through Sep 2022 reached -$2.0 million, down 162.77%, while the annual FY2025 figure was $377987.0, 206.08% up from the prior year.
  • Change in Receivables for Q3 2022 was -$126678.0 at Edesa Biotech, down from $167697.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $7.6 million in Q1 2021 and bottomed at -$3.6 million in Q2 2021.
  • The 5-year median for Change in Receivables is -$11120.5 (2018), against an average of $77424.4.
  • The largest annual shift saw Change in Receivables crashed 3402.16% in 2019 before it soared 41930.05% in 2021.
  • A 5-year view of Change in Receivables shows it stood at -$3109.0 in 2018, then plummeted by 3402.16% to -$108882.0 in 2019, then skyrocketed by 31.0% to -$75127.0 in 2020, then surged by 676.08% to $432792.0 in 2021, then plummeted by 129.27% to -$126678.0 in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Change in Receivables are -$126678.0 (Q3 2022), $167697.0 (Q2 2022), and -$2.5 million (Q1 2022).